

МІНІСТЕРСТВО ОХОРОНИ ЗДОРОВ'Я УКРАЇНИ
НАЦІОНАЛЬНИЙ ФАРМАЦЕВТИЧНИЙ УНІВЕРСИТЕТ
ІНСТИТУТ ПІДВИЩЕННЯ КВАЛІФІКАЦІЇ СПЕЦІАЛІСТІВ ФАРМАЦІЇ
КАФЕДРА ОРГАНІЗАЦІЇ, ЕКОНОМІКИ ТА УПРАВЛІННЯ ФАРМАЦІЄЮ

**ПІДГОТОВКА СПЕЦІАЛІСТІВ ФАРМАЦІЇ
В РАМКАХ КОНЦЕПЦІЇ
«НАВЧАННЯ ПРОТЯГОМ ЖИТТЯ
(LIFE LONG LEARNING)»:
НАУКА, ОСВІТА, ПРАКТИКА**

**МАТЕРІАЛИ ІV НАУКОВО-ПРАКТИЧНОЇ
ІНТЕРНЕТ КОНФЕРЕНЦІЇ
З МІЖНАРОДНОЮ УЧАСТЮ, ЯКА ПРИСВЯЧЕНА
ПАМ'ЯТІ ПРОФ. ТОЛОЧКО ВАЛЕНТИНА МИХАЙЛОВИЧА**

21 листопада 2025 року

**FROM MOLECULES TO MEDICINES; INTEGRATING AI,
BIOPHARMACY, AND NATURAL PRODUCT-BASED THERAPIES**

Michael Tarapata, Kukhtenko Oleksandr, Manskiy Oleksandr

National University of Pharmacy, Kharkiv, 61002, Ukraine

The Department of Pharmacy and Industrial Technology

automcorporation@gmail.com

Embracing collaborative innovation, the pharmaceutical sector can move towards a more holistic, effective, and patient-centered future, drawing strength from both cutting-edge technology and invaluable traditional wisdom.

Michael Tarapata

Introduction. The modern pharmaceutical industry is a dynamic and rapidly evolving sector, tasked with the relentless pursuit of novel therapeutic agents to respond to areas of significant medical need. For decades, the development of small molecule drugs, followed by the advent of large molecule biologics, has defined the trajectory of pharmaceutical innovation. However, the limitations of traditional approaches, coupled with exponential advancements in scientific understanding and technological capabilities, are ushering in a new era. Artificial Intelligence (AI) is no longer a futuristic concept but a potent tool revolutionizing every stage of the drug lifecycle, from initial target identification and compound screening to clinical trial design etc. Simultaneously, biotechnology continues to push the boundaries of what is therapeutically possible, with the development of sophisticated biologics, gene therapies, and cell therapies [1]. Biopharmacy, the discipline concerned with the design, formulation, and delivery of these complex pharmaceutical products, is grappling with novel challenges in ensuring efficacy, safety, and patient compliance [2]. Concurrently, there is a significant global resurgence of interest in traditional and complementary medicine (T&CM) systems. Homeopathy, characterized by its principle of "like cures like" and extreme dilutions, continues to be practiced, albeit

with persistent scientific debate regarding its underlying mechanisms and efficacy [3]. Herbal medicine, with its deep historical roots and vast repository of natural compounds, is gaining traction as a source of novel drug leads and as a therapeutic option in its own right, particularly in regions with rich ethnobotanical traditions and an increasing demand for natural remedies [4].

Apitherapy, the therapeutic use of honeybee products, is also experiencing renewed scientific investigation, with its constituent components showing promising pharmacological activities [5, 13].

This study aims to examine the current issues and interconnections between these disparate yet increasingly relevant fields, focusing on the technological, scientific, and regulatory challenges and opportunities they present. A particular emphasis will be placed on the complexities and potential of herbal medicine and apitherapy within the broader pharmaceutical paradigm.

Aim. The primary aim of this research paper is to provide a comprehensive review of the current issues and advancements in pharmaceutical technology, artificial intelligence (AI), biotechnology, biopharmacy, homeopathy, herbal medicine, and apitherapy. Specifically, the purpose of this paper is to:

Identify and analyze the key challenges and opportunities presented by the integration of AI in pharmaceutical research and development.

Analyze the advancements and challenges of modern biotechnology and biopharmacy in the development and delivery of novel therapeutic agents.

Examine the scientific standing, challenges, and potential of homeopathy in the contemporary medical landscape.

To analyze the current issues surrounding herbal medicine, including standardization, quality control, scientific validation, and regulatory integration, with a focus on its potential for novel drug discovery and therapeutic application.

Investigate the scientific basis, therapeutic applications, and challenges in the utilization of apitherapy and its constituent products.

Explore the interdependencies and potential synergies between traditional/natural product-based medicine and modern pharmaceutical approaches.

Provide evidence-based recommendations for future research, development, and integration of these diverse modalities.

Materials and Methods. This study include practical research and comprehensive data review employing a systematic approach to synthesize information from a wide range of academic and scientific sources. The methodology involved the following steps:

Analyze of practical researches and clinical results.

Data search strategy, a systematic search was conducted across several reputable academic databases and reputable offline and online resources.

Including of a broad spectrum of scientific journals, of those in pharmaceutical sciences, biotechnology, and chemistry.

Open-access research, including those relevant to specific therapeutic areas.

Articles were specifically sought from journals focusing on natural products, traditional medicine, and ethno pharmacology, such as the Chinese journal of natural medicines, journal of traditional Chinese medical sciences.

Reputable organizational sources e.g., world health organization WHO, regulatory bodies were considerate for guidelines and information.

Emphasis was placed on studies that presented original research, analyses, or comprehensive reviews of issues.

Particular attention was paid to studies that provided empirical data, mechanistic insights, or novel approaches to address the identified issues within herbal medicine and apitherapy. The synthesis aimed to present a balanced perspective, acknowledging both the potential and limitations of each area.

Results and Discussion. The pharmaceutical landscape is shaped by a range of factors, each presenting unique challenges and opportunities for innovation.

Pharmaceutical technology, the bedrock of drug development and manufacturing, is being profoundly reshaped by AI. There are many issues:

Drug discovery and development acceleration: AI algorithms are demonstrating remarkable efficiency in identifying novel drug targets, predicting molecular properties, screening vast compound libraries, and optimizing lead

compounds. This can significantly reduce the time and cost associated with early-stage drug discovery [6]. However, challenges persist in validating AI predictions through experimental means, the potential for bias in training data leading to skewed results, and the need for specialized expertise to develop and interpret AI models.

Personalized medicine and targeted patient grouping. AI can analyze complex genomic, proteomic, and clinical datasets to identify patient subgroups most likely to respond to specific therapies, paving the way for truly personalized medicine. The issue here is data privacy and security, ethical considerations surrounding data ownership and consent, and the regulatory frameworks needed to approve AI-driven diagnostic and therapeutic recommendations [7]. Furthermore, the integration of AI into existing healthcare systems requires significant infrastructure and training.

Clinical trial optimization. AI can optimize trial design, predict patient recruitment rates, monitor trial progress in real-time, and identify adverse events more rapidly. The challenge lies in the interpretability of AI predictions for regulatory bodies and the need for robust validation of AI-driven insights before they influence to trial decisions.

Pharmaceutical manufacturing & QC. AI can enhance manufacturing process control, to predict equipment failures, and improve supply chain management. The issue is the high initial investment, the need for skilled personnel, and the validation of AI-driven quality assurance systems to meet stringent regulatory standards.

Biotechnology and Biopharmacy. Biotechnology has revolutionized medicine by enabling the production of complex biological drugs, including monoclonal antibodies, recombinant proteins, gene therapies, and cell therapies.

Advancements in biologics. The development of biosimilars and novel biologics continues to expand treatment options for chronic and life-threatening diseases. The issue remains the high cost of development and manufacturing, which translates to high patient costs. Furthermore, the complexity of these molecules makes their characterization, stability, and immunogenicity assessment challenging.

Gene and cell therapies. These cutting-edge therapies offer the potential for one-time cures, but they face significant challenges. These include the complexity of

delivery vectors, potential off-target effects, long-term safety monitoring, and the astronomical manufacturing costs and scalability issues [1]. Regulatory pathways for these novel modalities are still evolving.

Biopharmacy challenges. Biopharmacy plays a crucial role in translating biotechnological breakthroughs into viable medicines. Key issues include:

Formulation and stability. Biologics are notoriously sensitive to environmental conditions (temperature, light, shear stress), making formulation and ensuring long-term stability a significant hurdle. This impacts storage, transportation, and shelf-life.

Delivery systems. Developing effective and patient-friendly delivery systems for biologics (e.g., oral delivery for large molecules, sustained-release formulations) are an ongoing challenge.

Immunogenicity. The potential for the body to develop an immune response against biological drugs can reduce efficacy and cause adverse reactions. Managing and predicting immunogenicity is a critical concern [2].

Homeopathy. Homeopathy, based on the principles of *similia similibus curentur* (like cures like) and the use of highly diluted substances, remains a controversial area in scientific discourse.

Scientific standing and efficacy. The overwhelming consensus within the scientific and medical communities, supported by numerous systematic reviews and meta-analyses, is that homeopathic remedies are not more effective than placebo [3, 8]. The core principles of homeopathy, particularly the idea that extreme dilutions retain therapeutic effects, contradict fundamental laws of chemistry and physics.

Current Issues:

Lack of robust evidence. Despite decades of research, there is a persistent lack of high-quality, reproducible evidence demonstrating the efficacy of homeopathy beyond the placebo effect. Methodological flaws in existing positive studies are frequently cited.

Regulatory and public health concerns. The promotion and acceptance of homeopathy as a substitute for evidence-based medical treatments can pose significant public health risks, particularly for serious conditions. Regulatory bodies

in many countries have strict guidelines on how homeopathic products can be marketed to avoid misleading claims.

Placebo effect exploration. While homeopathy itself lacks specific efficacy, the scientific community continues to explore the mechanisms and impact of the placebo effect, which can be substantial in patient care.

Herbal medicine. Herbal medicine, long a foundational component of global healthcare systems, is undergoing a renewed surge of interest fueled by its extensive ethnobotanical heritage and potential as a source of novel therapeutic compounds. The associated challenges are multifaceted and complex:

Standardization and quality control. This is arguably the most critical issue. Unlike synthetic drugs with well-defined chemical structures and purity profiles, herbal products are complex mixtures of phytochemicals.

Variability. The bioactives of medicinal plants can vary significantly due to factors such as geographical origin, climate, soil conditions, harvest time, and post-harvest processing [4]. This makes it difficult to ensure batch-to-batch consistency.

Lack of standardization. Standardizing extracts to a specific marker compound or a defined spectrum of bioactive compounds is essential for reproducible therapeutic effects. However, identifying critical bioactive compounds and developing appropriate analytical methods remains a challenge for many herbs.

Contamination - falsification. Herbal products are susceptible to contamination with heavy metals, pesticides, microbial pathogens, and adulteration with undeclared conventional drugs or cheaper plant materials. This poses significant safety risks [9].

Scientific validation and evidence generation. While historical use provides a basis for investigation, rigorous scientific validation is crucial.

Mechanistic understanding. Elucidating the precise pharmacological mechanisms of action for complex herbal mixtures is challenging. Identifying which compounds are responsible for the observed effects and how they interact synergistically is an active area of research.

Homeopathy. Homeopathy, based on the principles of *similia similibus curentur* (like cures like) and the use of highly diluted substances, remains a controversial area in scientific discourse.

Scientific standing and efficacy. The overwhelming consensus within the scientific and medical communities, supported by numerous systematic reviews and meta-analyses, is that homeopathic remedies are not more effective than placebo [3, 8]. The core principles of homeopathy, particularly the idea that extreme dilutions retain therapeutic effects, contradict fundamental laws of chemistry and physics.

Current Issues:

Lack of robust evidence. Despite decades of research, there is a persistent lack of high-quality, reproducible evidence demonstrating the efficacy of homeopathy beyond the placebo effect. Methodological flaws in existing positive studies are frequently cited.

Regulatory and public health concerns. The promotion and acceptance of homeopathy as a substitute for evidence-based medical treatments can pose significant public health risks, particularly for serious conditions. Regulatory bodies in many countries have strict guidelines on how homeopathic products can be marketed to avoid misleading claims.

Placebo effect exploration. While homeopathy itself lacks specific efficacy, the scientific community continues to explore the mechanisms and impact of the placebo effect, which can be substantial in patient care.

Herbal medicine, long a foundational component of global healthcare systems, is undergoing a renewed surge of interest fueled by its extensive ethnobotanical heritage and potential as a source of novel therapeutic compounds. The associated challenges are multifaceted and complex:

Standardization and quality control. This is arguably the most critical issue. Unlike synthetic drugs with well-defined chemical structures and purity profiles, herbal products are complex mixtures of phytochemicals.

Variability. The chemical composition of medicinal plants can vary significantly due to factors such as geographical origin, climate, soil conditions,

harvest time, and post-harvest processing [4]. This makes it difficult to ensure batch-to-batch consistency.

Lack of standardization. Standardizing extracts to a specific marker compound or a defined spectrum of bioactive compounds is essential for reproducible therapeutic effects. However, identifying critical bioactive compounds and developing appropriate analytical methods remains a challenge for many herbs.

Contamination and falsification. Herbal products are susceptible to contamination with heavy metals, pesticides, microbial pathogens, and adulteration with undeclared conventional drugs or cheaper plant materials. This poses significant safety risks [9].

Scientific validation and evidence generation. While historical use provides a basis for investigation, rigorous scientific validation is crucial.

Mechanistic understanding. Elucidating the precise pharmacological mechanisms of action for complex herbal mixtures is challenging. Identifying which compounds are responsible for the observed effects and how they interact synergistically is an active area of research.

Clinical trials. Conducting high-quality, placebo-controlled clinical trials for herbal medicines can be difficult due to issues of standardization, blinding, and the potential for variability in patient response. However, advancements in study design and analytical techniques are improving the quality of evidence [4].

Drug discovery potential. Herbal resources are an invaluable source of lead compounds for drug discovery. For example, paclitaxel (Taxol) derived from *Taxus brevifolia* and artemisinin from *Artemisia annua* are prime examples of life-saving drugs originating from plants [10]. The ongoing challenge is to systematically screen and characterize these natural products for novel therapeutic potential.

Regulatory integration. Integrating herbal medicines into mainstream pharmaceutical regulatory frameworks poses challenges. Different countries have varying regulations, ranging from treating them as dietary supplements to stringent pharmaceutical regulations. Harmonization of these regulations is needed to ensure both safety and accessibility.

Species identification and authentication. Precise taxonomic identification of plant materials is essential to ensure the safety and efficacy of herbal medicines. Misidentification can result in the inclusion of ineffective species or, in severe cases, toxic plants with significant health risks. Molecular techniques and robust taxonomic standards are crucial for authentication [4].

Apitherapy. Apitherapy utilizes products derived from honeybees, including honey, pollen, propolis, royal jelly, and bee venom, for therapeutic purposes.

Therapeutic applications and scientific basis:

Honey. Renowned for its antimicrobial, anti-inflammatory, and wound-healing properties. Medical-grade honey, particularly Manuka honey, has been scientifically validated for wound care and offers a natural alternative to conventional dressings [5]. Research is also exploring its potential in gastrointestinal health and as an antioxidant.

Propolis. A resinous mixture collected by bees, propolis exhibits broad-spectrum antimicrobial, anti-inflammatory, antioxidant, and immunomodulatory activities. Its use in oral hygiene products and wound care is well-established, and ongoing research investigates its potential in cancer therapy and for its antiviral properties [11, 15].

Bee Venom. Contains a complex mixture of peptides, enzymes, and amines, notably melittin and apamin. Bee venom therapy (BVT) has been historically used for inflammatory conditions like arthritis. Modern research is investigating its potential in autoimmune diseases (e.g., multiple sclerosis), pain management, and as an anti-cancer agent due to melittin's cytotoxic effects on cancer cells [5, 12].

Current Issues:

Standardization and quality control. Similar to herbal medicine, the composition of bee products can vary depending on the bee species, geographical location, floral sources, and processing methods. Standardizing extracts for consistent therapeutic outcomes is a significant challenge. For bee venom, ensuring the correct dosage and identifying the active components are critical for safety and efficacy [5].

Allergic reactions and safety. Bee venom can cause severe allergic reactions, including anaphylaxis, in sensitized individuals. Careful screening for allergies and

controlled administration are paramount. The safety of some propolis preparations, particularly regarding potential interactions with other medications, also requires careful consideration [11].

Evidence generation. While evidence for honey in wound care is robust, more high-quality clinical trials are needed to substantiate the therapeutic claims for other apitherapeutic products, particularly for systemic conditions. Understanding the synergistic effects of various compounds within these complex matrices is a research priority [5].

Regulatory status. Apitherapeutic products often fall into a regulatory grey area, being treated as food supplements or traditional remedies rather than strictly regulated pharmaceuticals, which can sometimes lead to inconsistent quality and marketing claims.

Interdependencies and synergies. The lines between these fields are becoming increasingly blurred, leading to exciting opportunities:

AI-driven natural product discovery. AI can accelerate the identification of novel bioactive compounds from herbal and apitherapeutic sources by analyzing complex phytochemical profiles and predicting their pharmacological activities.

Biotechnology for natural product production. Genetic engineering and synthetic biology approaches can be used to enhance the production of specific valuable compounds found in medicinal plants or to create recombinant versions of bee venom peptides for therapeutic use, ensuring purity and scalability [14].

Biopharmacy for natural product delivery. Advanced drug delivery systems developed in biopharmacy can be applied to enhance the bioavailability and targeted delivery of herbal extracts and apitherapeutic compounds, overcoming limitations of oral absorption or local application.

Integrative medicine. A growing movement advocates for integrating evidence-based T&CM modalities with conventional Western medicine. This requires robust scientific validation of T&CM practices and open dialogue between practitioners and researchers from all disciplines.

Conclusions. The pharmaceutical sector is navigating a transformative phase, embracing transformative technologies like AI and sophisticated biotechnological approaches while simultaneously re-evaluating and re-validating historical therapeutic systems. AI and biotechnology offer unprecedented potential to accelerate drug discovery, personalize treatments, and develop novel therapies, but they also present significant ethical, regulatory, and technical challenges. Biopharmacy stands as the crucial link, tasked with ensuring these complex innovations translate into safe and effective medicines.

Herbal medicine and apitherapy, rooted in centuries of empirical knowledge, are increasingly recognized for their therapeutic value and as rich sources of novel drug leads. However, their widespread integration into modern healthcare hinges on addressing persistent issues of standardization, robust scientific validation, and rigorous quality control. The variability inherent in natural products necessitates sophisticated analytical methods and well-designed clinical trials to establish their efficacy and safety beyond doubt.

The future of pharmaceutical innovation likely lies in the synergistic interplay between these diverse fields. AI can unlock the secrets of natural bioactives (product chemistry), biotechnology can optimize the production of valuable compounds, and biopharmacy can devise innovative delivery systems for both synthetic and natural therapeutics.

References

1. Paul S., et al. Biotechnology in drug discovery and development // Drug Discovery Today. - 2021. - Vol. 26, No. 1. - P. 222-227.
2. Singh J., Roberts C. J. Biopharmaceutics challenges of protein drug delivery // Biotechnology and Bioengineering. - 2018. - Vol. 115, No. 9. - P. 2129-2140.
3. Shang A., et al. Are the effects of homoeopathy borne out by rigorous scientific evidence? // The Lancet. - 2005. - Vol. 366, No. 9487. - P. 726-732.
4. Cragg G. M., Newman D. J. Natural products: a continuing source of novel drug leads // Biochimica et Biophysica Acta (BBA) - General Subjects. - 2013. - Vol. 1830, No. 6. - P. 3670-3695.

5. Bogdanov S., et al. Honey - a real medicine // International Journal of Food Properties. - 2008. - Vol. 11, No. 2. - P. 315-327.
6. Vamathevan J., et al. Applications of machine learning in drug discovery and develop. // Nature Reviews Drug Discovery. - 2019. - Vol. 18, No. 6. - P. 463-477.
7. Yu K. H., Beam A. L., Kohane I. S. Artificial intelligence in healthcare // Nature Biomedical Engineering. - 2018. - Vol. 2, No. 7. - P. 451-471.
8. Ernst E., Can A. Homeopathy: what does the evidence say? // The Medical Journal of Australia. - 2002. - Vol. 177, No. 12. - P. 691-694.
9. Khan I. A. Importance of standardization in herbal medicines // Chinese Journal of Natural Medicines. - 2008. - Vol. 6, No. 1. - P. 1-5.
10. Newman D. J., Cragg G. M. Natural products as sources of new drugs over the nearly 4 decades of the drug discovery process // Journal of Natural Products. - 2020. - Vol. 83, No. 3. - P. 770-777.
11. Bankova V. S. Propolis: A complex natural product with significant biological activity // Journal of Asian Scientific Res. - 2019. - Vol. 9, No. 9. - P. 191-214.
12. Han S. M., et al. Bee venom therapy: An overview of its potential therapeutic applications // Asian Journal of Advanced Research and Reports. - 2021. - Vol. 15, No. 2. - P. 49-63.
13. Tarapata, M. O., Kukhtenko, O. S., Manskyi, O. A., & Bezrukaviy, Ye. A. (n.d.). The use of the medicinal plant raw material and bee products in the treatment of dermatological diseases. 94-101. <https://doi.org/10.24959/nphj.25.166>.
14. Tarapata M., Kukhtenko O., Trutaev S. Synergy of bee products with medicinal herbs // V International Scientific and Practical Conference "Problems and Achievements of Modern Biotechnology". - March 28, 2025.
15. Tarapata M. O., Kukhtenko O. S. Some aspects of biologically active substances of bee products - propolis, and wound-healing // IV International Scientific and Practical Internet Conference "Problems and Achievements of Modern Biotechnology". - 2023. - P. 104-107.